‌ UNITED ~~STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549~~STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (~~Date~~date of earliest event reported): August 828, 2024

BIOLASE, INC.

(Exact name of ~~Registrant~~registrant as ~~Specified~~specified in ~~Its~~its ~~Charter~~charter)

Delaware	001-36385	~~001-36385~~	87-0442441
(State or Other Jurisdictionof Incorporation)		(Commission File Number)	(IRS EmployerIdentification No.)
(State or other jurisdiction of incorporation)	(Commission File No.)		(IRS Employer Identification No.)
27042 Towne Centre Drive, Suite 270
Lake Forest, California			92610
(Address of Principal Executive Offices)			(Zip Code)
Registrant’s Telephone Number, Including Area Code: (949) 361-1200
Not Applicable

~~(Former~~27042 ~~Name~~Towne orCentre ~~Former Address~~Drive, ifSuite ~~Changed~~270 ~~Since Last Report)~~

Lake Forest, California 92610

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (949) 361-1200

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class ~~TradingSymbol~~Trading Symbol(s) Name of each exchange on which registered N/A N/A N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by ~~check~~checkmark ~~mark~~ if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item  2.0204. Triggering ~~Results~~Events ofThat ~~Operations~~Accelerate ~~and~~or Increase a Direct Financial ~~Condition~~Obligation or an Obligation under an Off-Balance Sheet Arrangement.

On August 822, 2024, BIOLASE, Inc., a Delaware corporation (the "“Company"”) ~~issued~~received a ~~press~~written ~~release~~notice ~~announcing~~(the ~~its~~“Default ~~financial~~Notice”) ~~results~~from ~~for~~SWK ~~the~~Funding ~~second~~LLC ~~quarter~~as ~~ended~~agent ~~June~~(the 30“Agent”) and a lender, ~~2024.~~under Athat ~~copy~~certain ofCredit ~~the~~Agreement, ~~press~~dated ~~release~~November is9, ~~furnished~~2018 (as ~~Exhibit~~amended, ~~99.1~~restated, supplemented or otherwise modified from time to ~~this~~time, ~~Current~~the ~~Report~~“Credit onAgreement”) ~~Form~~by ~~8-K~~and among the Company, the lender parties thereto (each a “Lender” and istogether, ~~hereby~~the ~~incorporated~~“Lenders”), ~~herein~~and bythe ~~reference~~Agent, that an alleged Event of Default (as defined in the Credit Agreement) has occurred.

The ~~information~~Default ~~contained~~Notice inspecifies ~~this~~that ~~Item~~an ~~2.02,~~Event ~~including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes~~ of ~~Section~~Default 18has ofoccurred under the ~~Securities~~Credit ~~Exchange~~Agreement ~~Act~~due ofto ~~1934 (~~the ~~“Exchange~~Company’s ~~Act”),~~failure asto ~~amended,~~make orcertain ~~otherwise~~payments ~~subject~~ to the ~~liabilities~~Agent ofunder ~~that~~the ~~section,~~Credit ~~and~~Agreement ~~such~~on ~~information~~the ~~shall~~applicable ~~not~~Payment beDate ~~deemed~~(as todefined bein ~~incorporated~~the byCredit ~~reference~~Agreement) ~~into any~~ of ~~the~~August ~~Company’s~~15, ~~filings~~2024 ~~under~~or ~~the~~within ~~Securities~~five ~~Act~~business ofdays ~~1933,~~thereof ~~as amended, or~~ (the ~~Exchange~~“August ~~Act~~Payment Date”).

~~Item~~In 9the Default Notice, the Agent states that the Agent, on behalf of the Agent and Lenders, has extended the August Payment Date to August 30, 2024 (the “Extended Payment Date”); provided, however, the Extended Payment Date is inclusive of any cure period.01 ~~Financial~~The ~~Statements~~Default Notice further states that except as expressly set forth therein, all of the other terms, provisions and ~~Exhibits~~conditions of the Credit Agreement and the other loan documents shall remain and continue in full force and effect, and the Agent and each Lender reserve all of their respective rights, privileges and remedies under the Credit Agreement, the loan documents, each other agreement and any other contracts or instruments executed by the Company for the benefit of the Agent or such Lender.

~~d) Exhibits~~.

Exhibit No.		Description
99.1		Press Release of BIOLASE dated August 8, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BIOLASE, INC.
Date: August 8, 2024	By	/s/ JENNIFER BRIGHT
		Name: Jennifer Bright
		Title: Chief Financial Officer

‌




	‌	BIOLASE, INC.

Date: August 28, 2024	‌	By:	/s/ John R. Beaver
	‌	Name:	John R. Beaver
		Title:	President and Chief Executive Officer

‌

Filing Compare · BIOLASE, INC